2 weeks Ago By ABMN Staff
Regulus Therapeutics ( NASDAQ:RGLS – Get Free Report ) ‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock.
Several other brokerages have also recently weighed in on RGLS. Oppenheimer reiterated an “outperform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, August 14th.
StockNews.com raised Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company.
According to data from MarketBeat.com, Regulus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.
Read Our Latest Stock Report on RGLS Regulus Therapeutics Trading Up 10.6 % Regulus Therapeutics ( NASDAQ:RGLS – Get Free Report ) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.
21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03).
Analysts forecast that Regulus Therapeutics will post -0.8 EPS for the current year. Institutional Inflows and Outflows Several large investors have recently bought and sold shares of the stock.
Creative Planning bought a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at about $26,000. SG Americas Securities LLC bought a new position in Regulus Therapeutics during the 3rd quarter worth approximately $33,000. Rhumbline Advisers acquired a new position in shares of Regulus Therapeutics in the 2nd quarter worth approximately $136,000.
Tyche Wealth Partners LLC increased its position in shares of Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 95,694 shares during the period.
Finally, Renaissance Technologies LLC raised its stake in Regulus Therapeutics by 56.4% during the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 42,600 shares during the last quarter.
92.38% of the stock is owned by institutional investors. About Regulus Therapeutics ( Get Free Report ) Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. Further Reading Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
